How Jazz Pharmaceuticals Is Positioned before Its Q2 2018 Results
Jazz Pharmaceuticals (JAZZ) generated revenue of $444.6 million in the first quarter, reflecting an ~18% YoY (year-over-year) rise. Xyrem and Vyxeos primarily pushed the company’s revenue growth in the quarter.